LHCGR
Lutropin-choriogonadotropic hormone receptor
As of the edition of 20 October 2026, LHCGR (lutropin-choriogonadotropic hormone receptor, UniProt P22888) has 4 drugs tested at it and 6 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22888
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Hormones; Cancer; Inherited and neonatal; Nutrition and metabolism; Nervous system; Injuries
- Registered trials of its drugs
- 165
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Gonadotropin, chorionic | Marketed | Phase 4 | Ended 1985 |
| Menotropins | Marketed | Phase 4 | Ended 1987 |
| Choriogonadotropin alfa | Marketed | Phase 4 | Ended 2012 |
| Lutropin alfa | Marketed | Phase 4 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Boiron | Route B |
The other 5 companies at LHCGR
In the product6 companies in all; 5 are not named here, and no score is.
See the 6 companies at LHCGR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.